1. Andersson M, Persson M, Kjellgren A. Psychoactive substances as a last resort – a qualitative study of self-treatment of migraine and cluster headaches. Harm Reduct J 2017; 14: 1-10.
2.
Barker SA. Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT. Psychopharmacology 2022; 239 (6): 1749-63.
3.
Barker SA. N,N-Dimethyltryptamine (DMT), an endogenous hallucinogen: Past, present, and future research to determine its role and function. Front Neurosci 2018; 12: 536.
4.
Batalla M. All-natural 5-MeO-DMT sigma receptor 1 agonist and its therapeutic impact in mental and neurodegenerative diseases through mitochondrial activation. Science Reviews. Biology 2023; 2 (2): 1-20.
5.
Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology 2023; 48: 104-12.
6.
Callaway JC, Grob CS. Ayahuasca Preparations and Serotonin Reuptake Inhibitors: A Potential Combination for Severe Adverse Interactions. Journal of Psychoactive Drugs 1998; 30: 367-9.
7.
Cameron LP, Benson CJ, Dunlap LE et al. Effects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression. ACS Chem Neurosci 2018; 9: 1582-90.
8.
Carbonaro TM, Gatch MB. Neuropharmacology of N,N-dimethyltryptamine. Brain Res Bull 2016; 126: 74-88.
9.
Carhart-Harris R, Nutt D. Serotonin and brain function: a tale of two receptors. J Psychopharmacol 2017; 31: 1091-120.
10.
Carhart-Harris R, Giribaldi B, Watts R et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med 2021; 384: 1402-11.
11.
Dean JG, Liu T, Huff S et al. Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain. Sci Rep 2019; 9: 9333.
12.
Dos Santos RG, Hallak JEC. Effects of the Natural β-Carboline Alkaloid Harmine, a Main Constituent of Ayahuasca, in Memory and in the Hippocampus: A Systematic Literature Review of Preclinical Studies. Journal of Psychoactive Drugs 2017; 49: 1-10.
13.
D’Souza DC, Syed SA, Flynn LT et al. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology 2022; 47: 1854-62.
14.
Eckernäs E, Timmermann C, Carhart‐Harris R et al. N,N‐dimethyltryptamine affects electroencephalography response in a concentration‐dependent manner – A pharmacokinetic/pharmacodynamic analysis. CPT Pharmacomet Syst Pharmacol 2023; 12: 474-86.
15.
Fanibunda SE, Deb S, Maniyadath B et al. Serotonin regulates mitochondrial biogenesis and function in rodent cortical neurons via the 5-HT 2A receptor and SIRT1-PGC-1α axis. Proc Natl Acad Sci U S A 2019; 116: 11028-37.
16.
Fanibunda SE, Vaidya VA. Serotonin minting new mitochondria in cortical neurons: implications for psychopathology. Neuropsychopharmacol 2021; 46: 259-60.
17.
Fissler P, Vandersmissen A, Filippi M et al. Effects of serotonergic psychedelics on mitochondria: Transdiagnostic implications for mitochondria-related pathologies. Journal of Psychopharmacology 2023; 37 (7): 679-86.
18.
Filippi M, Krähenmann R, Fissler P. The Link Between Energy-Related Sensations and Metabolism: Implications for Treating Fatigue. Front Psychol 2022; 13: 920556.
19.
Fontanilla D, Johannessen M, Hajipour AR et al. The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator. Science 2009; 323: 934-7.
20.
Frecska E, Kovacs A. The protective role of dimethyltryptamine and its analogues against ischemia-reperfusion injury: Commentary. Neuroscience 2021; 2: 39-42.
21.
Gardner D, Riet-Correa F, Lemos D et al. Teratogenic effects of Mimosa tenuiflora in a rat model and possible role of N-methyl-and N,N-dimethyltryptamine. Journal of agricultural and food chemistry 2014; 62: 7398-401.
22.
Gattuso J J, Perkins D, Ruffell S et al. Default Mode Network Modulation by Psychedelics: A Systematic Review. Int J Neuropsychopharmacol 2023; 26 (3), 155-88.
23.
Goguadze N, Zhuravliova E, Morin D et al. Sigma-1 Receptor Agonists Induce Oxidative Stress in Mitochondria and Enhance Complex I Activity in Physiological Condition but Protect Against Pathological Oxidative Stress. Neurotox Res 2019; 35: 1-18.
24.
Good M, Joel Z, Benway T et al. Pharmacokinetics of N,N-dimethyltryptamine in Humans. Eur J Drug Metab Pharmacokinet 2023; 48 (3): 311-27.
25.
Griffiths RR, Johnson MW, Richards WA et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol 2018; 32: 49-69.
26.
Gumpper RH, Roth BL. Psychedelics: preclinical insights provide directions for future research. Neuropsychopharmacology 2023; DOI: 10.1038/s41386-023-01567-7
27.
Inserra A. Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process. Front Pharmacol 2018; 9: 330.
28.
James E, Keppler J, Robertshaw TL et al. N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine. Human Psychopharmacology: Clinical and Experimental 2022; 37: e2835.
29.
Jiménez JH, Bouso JC. Significance of mammalian N,N-dimethyltryptamine (DMT): A 60-year-old debate. J Psychopharmacol 2022; 36: 905-19.
30.
Kagan S. The content of complex psychedelic experiences resulting from inhalation of N,N-dimethyltryptamine. J Psychedelic Stud 2023; 6: 222-31
31.
Kaplan J, Mandel LR, Stillman R et al. Blood and urine levels of N,N-dimethyltryptamine following administration of psychoactive dosages to human subjects. Psychopharmacologia 1974; 38: 239-45.
32.
Kargbo RB. Application of Deuterated N, N-Dimethyltryptamine in the Potential Treatment of Psychiatric and Neurological Disorders. ACS Med Chem Lett 2022; 13: 1402-4.
33.
Keiser MJ, Setola V, Irwin JJ et al. Predicting new molecular targets for known drugs. Nature 2009; 462: 175-81.
34.
Kelley DP, Venable K, Destouni A et al. Pharmahuasca and DMT Rescue ROS Production and Differentially Expressed Genes Observed after Predator and Psychosocial Stress: Relevance to Human PTSD. ACS Chem Neurosci 2022; 13: 257-74.
35.
Kozlowska U, Nichols C, Wiatr K et al. From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders. J Neurochem 2022; 162: 89-108.
36.
Luan L, Eckernäs E, Ashton M et al. Psychological and physiological effects of extended DMT. Journal of Psychopharmacology 2023; DOI: 02698811231196877.
37.
Ly C, Greb AC, Cameron LP et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep 2018; 23: 3170-82.
38.
Mohapatra SR, Sadik A, Sharma S et al. Hypoxia Routes Tryptophan Homeostasis Towards Increased Tryptamine Production. Front Immunol 2021; 12: 590532.
39.
Morales-García JA, De La Fuente Revenga M, Alonso-Gil S et al. The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro. Sci Rep 2017; 7: 5309.
40.
Morales-García JA, Calleja-Conde J, Lopez-Moreno JA et al. N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo. Transl Psychiatry 2020; 10: 331.
41.
Nemes B, Pető K, Németh N et al. N,N-dimethyltryptamine prevents renal ischemia-reperfusion injury in a rat model. In: Transplant Proc 2019; 51 (4): 1268-75.
42.
Olson DE. Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity. Biochemistry 2022; 61 (3): 127-36.
43.
Olson DE. Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics. J Exp Neurosci 2018; 12: 1179069518800508.
44.
Owen L, Sunram-Lea SI. Metabolic Agents that Enhance ATP can Improve Cognitive Functioning: A Review of the Evidence for Glucose, Oxygen, Pyruvate, Creatine, and l-Carnitine. Nutrients 2011; 3: 735-55.
45.
Peto K, Nemeth N, Mester A et al. Hemorheological and metabolic consequences of renal ischemia-reperfusion and their modulation by N,N-dimethyl-tryptamine on a rat model. Clinical Hemorheology and Microcirculation 2018; 70: 107-17.
46.
Ray TS. Psychedelics and the human receptorome. PLoS One 2010; 5: e9019.
47.
Riba J, Romero S, Grasa E et al. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology 2006; 186: 93-8.
48.
Ruffell SGD, Netzband N, Tsang W et al. Ceremonial Ayahuasca in Amazonian Retreats – Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study. Front Psychiatry 2021; 12: 687615.
49.
Saeger HN, Olson DE. Psychedelic‐inspired approaches for treating neurodegenerative disorders. J Neurochem 2021; 162 (1), 109-27.
50.
Sampedro F, de la Fuente Revenga M, Valle M et al. Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities. International Journal of Neuropsychopharmacology 2017; 20: 698-711.
51.
Santos GHDM, Rodrigues LS, Rocha JM et al. Neural Network Modulation of Ayahuasca: A Systematic Review of Human Studies. Psychoactives 2023; 2: 76-91.
52.
Scott G, Carhart-Harris RL. Psychedelics as a treatment for disorders of consciousness. Neurosci Conscious 2019; 2019 (1): niz003; DOI: 10.1093/nc/niz003.
53.
Siegel JS, Nicol GE. Plasticity markers in the human brain associated with rapid antidepressants. Neuropsychopharmacology 2023; 48: 223-4.
54.
Strassman RJ, Qualls CR, Berg LM. Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Biological psychiatry 1996; 39: 784-95.
55.
Su T-P, Hayashi T, Vaupel DB. When the Endogenous Hallucinogenic Trace Amine N,N-Dimethyltryptamine Meets the Sigma-1 Receptor. Sci Signal 2009; 2 (61): pe12; DOI: 10.1126/scisignal.261pe12.
56.
Szabo A. Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities. Front Immunol 2015; 6: 358.
57.
Szabo A, Kovacs A, Riba J et al., The endogenous hallucinogen and trace amine N, N-dimethyltryptamine (DMT) displays potent protective effects against hypoxia via sigma-1 receptor activation in human primary iPSC-derived cortical neurons and microglia-like immune cells. Frontiers in neuroscience 2016; 10: 423.
58.
Szabó Í, Varga VÉ, Dvorácskó S et al. N,N-Dimethyltryptamine attenuates spreading depolarization and restrains neurodegeneration by sigma-1 receptor activation in the ischemic rat brain. Neuropharmacology 2021; 192: 108612.
59.
Timmermann C, Roseman L, Haridas S et al. Human brain effects of DMT assessed via EEG-fMRI. Proc Natl Acad Sci 2023; 120: e2218949120.
60.
Timmermann C, Roseman L, Schartner M et al. Neural correlates of the DMT experience assessed with multivariate EEG. Sci Rep 2019; 9: 16324.
61.
Timmermann C, Roseman L, Williams L et al. DMT Models the Near-Death Experience. Front Psychol 2018; 9: 1424.
62.
Turetzky RL. A Hermeneutic Phenomenology of the N,N-Dimethyltryptamine (DMT) Experience. Carpinteria 2022.
63.
Vargas MV, Dunlap LE, Dong C et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science 2023; 379: 700-06.
64.
Vollenweider F. Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis. Neuropsychopharmacology 1997; 16: 357-72.
65.
Vogt SB, Ley L, Erne L et al. Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants. Transl Psychiatry 2023; 13: 172.
66.
Więckiewicz G, Stokłosa I, Piegza M et al. Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. Pharmaceuticals 2021; 14: 793.
67.
Yritia M, Riba J, Ortuno J et al. Determination of N,N-dimethyltryptamine and β-carboline alkaloids in human plasma following oral administration of ayahuasca. Journal of Chromatography B 2002; 779: 271-81.
68.
Zhang J, Qian H, Zhao P et al. Rapid Hypoxia Preconditioning Protects Cortical Neurons From Glutamate Toxicity Through δ-Opioid Receptor. Stroke 2006; 37: 1094-9.
